CLRB logo

CLRBCellectar Biosciences Inc

$2.45
$0.03
(1.22%)
Today
Closed $2.48
$0.03
(1.21%)
After Hours
Updated: 06:57 PM EDT
EarningsAug 13
Mkt Cap$19.58M
Vol101,125.00
News
all
press releases
Cellectar Biosciences (CLRB) Upgraded to Buy: Here's What You Should Know
Cellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
News Placeholder
More News
News Placeholder
Has Centene (CNC) Outpaced Other Medical Stocks This Year?
Here is how Centene (CNC) and Cellectar Biosciences, Inc. (CLRB) have performed compared to their sector so far this year.
Zacks
News Placeholder
CLRB Stock Surged 27% Today – Here’s Why Retail Is Bullish About Cellectar’s Blood Cancer Trial Data
The biotech firm reported strong Phase 2 trial results for a blood cancer treatment, along with a $140 million fundraise to support the next stages of the trial.
Stocktwits
News Placeholder
Insider Signals and Potential Moonshots that Could Reset Valuations
Biotech and pharma markets are leading the way in a sharply selective environment at midday, where clinical data, insider conviction, and platform scalability are driving outsized moves while weaker narratives get left behind. $NTHI, $POET, $SDOT, $BDRX, $CLRB, $DOCN, $FSLY, $EWTX, $BLDP
24-7 Market News
News Placeholder
Cellectar Biosciences Stock Rallies As Blood Cancer Data Impresses
Cellectar releases Phase 2b CLOVER WaM data showing strong response rates and durability, alongside $140 million financing.read more...
Benzinga
News Placeholder
Markets On Fire: Biotech Breakthroughs and AI Mega-Deals Move Wall Street
$CLRB, $NTHI, $BLZE, $DGXX, $VRDN, $CYTK are among today's leading stocks
24-7 Market News
News Placeholder
Insights into Cellectar Biosciences's Upcoming Earnings
read more...
Benzinga
News Placeholder
Earnings Outlook For Cellectar Biosciences
read more...
Benzinga
News Placeholder
Cellectar Biosciences Stock Drops 17% On $5.8M Fundraise: Retail Awaits An ‘Impending’ Rally
The company announced that it now intends to utilize the net proceeds for working capital and general corporate purposes, in addition to funding the early-stage trial of its CLR 125 compound in triple-negative breast cancer.
Stocktwits
News Placeholder
All You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to Buy
Cellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
<
1
2
...
>

Advertisement|Remove ads.